TCM
PTCT icon

Timpani Capital Management’s PTC Therapeutics PTCT Stock Holding History

Timpani Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-53,058
Closed -$3.23M – 94
2015
Q1 		$3.23M Buy
53,058
+17,283
+48% +$1.05M 0.96% 55
2014
Q4 		$1.85M Buy
+35,775
New +$1.57M 0.73% 65

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return

Timpani Capital Management's PTCT Position: Q2 2015 in Review

Timpani Capital Management sold out of PTC Therapeutics (PTCT) in Q2 2015, closing a stake of 53,058 shares — an estimated $3.23M sold.

Timpani Capital Management first reported a position in PTCT in Q4 2014 and held it in 2 quarters. The position peaked at $3.23M in Q1 2015. 155 funds tracked by Wall St. Rank hold PTCT as of Q2 2015.

  • Timpani Capital Management reported no remaining PTC Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Timpani Capital Management sold 53,058 PTC Therapeutics shares in Q2 2015, an estimated $3.23M.
  • Timpani Capital Management first reported a position in PTC Therapeutics in Q4 2014 and held it in 2 quarters.
  • Timpani Capital Management's PTC Therapeutics position peaked at $3.23M in Q1 2015.
  • 155 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2015.

Based on Timpani Capital Management's 13F filing for Q2 2015, filed 12 Aug 2015.